Molecular docking and 3D-QSAR-based virtual screening of flavonoids as potential aromatase inhibitors against estrogen-dependent breast cancer

References

• Adlercreutz, H. (1995). Phytoestrogens: Epidemiology and a possible role in cancer protection. Environmental Health Perspectives, 103, 103–112.
   PubMed Web of Science ®Google Scholar
• Akamatsu, M. (2002). Current state and perspectives of 3D-QSAR. Current Topics in Medicinal Chemistry, 2, 1381–1394.10.2174/1568026023392887
   PubMedGoogle Scholar
• American Cancer Society. (2012). Cancer treatment and survivorship facts & figures 2012–2013. Retrieved from http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-033876.pdf
   Google Scholar
• American Cancer Society. (2013). Cancer facts & figures 2013. Retrieved from http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf
   Google Scholar
• Balunas, M. J., Su, B., Brueggemeier, R. W., & Kinghorn, A. D. (2008). Natural products as aromatase inhibitors. Anti-Cancer Agents in Medicinal Chemistry, 8, 646–682.10.2174/187152008785133092
   PubMed Web of Science ®Google Scholar
• Banting, L., Nicholls, P. J., Shaw, M. A., & Smith, H. J. (1989). Recent developments in aromatase inhibition as a potential treatment for oestrogen-dependent breast cancer. Progress in Medicinal Chemistry, 26, 253–298.10.1016/S0079-6468(08)70242-X
   PubMedGoogle Scholar
• Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., … Bourne, P. E. (2000). The protein data bank. Nucleic Acids Research, 28, 235–242.10.1093/nar/28.1.235
   PubMed Web of Science ®Google Scholar
• Bhatnagar, A. S. (2007). The discovery and mechanism of action of letrozole. Breast Cancer Research and Treatment, 105, 7–17.10.1007/s10549-007-9696-3
   PubMed Web of Science ®Google Scholar
• Brodie, A. M. H., & Njar, V. C. O. (1998). Aromatase inhibitors in advanced breast cancer: Mechanism of action and clinical implications. The Journal of Steroid Biochemistry and Molecular Biology, 66, 1–10.10.1016/S0960-0760(98)00022-3
   PubMed Web of Science ®Google Scholar
• Brueggemeier, R. W., Hackett, J. C., & Diaz-Cruz, E. S. (2005). Aromatase inhibitors in the treatment of breast cancer. Endocrine Reviews, 26, 331–345.10.1210/er.2004-0015
   PubMed Web of Science ®Google Scholar
• Brueggemeier, R. W., Richards, J. A., Joomprabutra, S., Bhat, A. S., & Whetstone, J. L. (2001). Molecular pharmacology of aromatase and its regulation by endogenous and exogenous agents. The Journal of Steroid Biochemistry and Molecular Biology, 79, 75–84.10.1016/S0960-0760(01)00127-3
   PubMed Web of Science ®Google Scholar
• Campos, S. M. (2004). Aromatase inhibitors for breast cancer in postmenopausal women. The Oncologist, 9, 126–136.10.1634/theoncologist.9-2-126
   PubMed Web of Science ®Google Scholar
• Costanzi, S., Tikhonova, I. G., Harden, T. K., & Jacobson, K. A. (2009). Ligand and structure-based methodologies for the prediction of the activity of G protein-coupled receptor ligands. Journal of Computer-Aided Molecular Design, 23, 747–754.10.1007/s10822-008-9218-3
   PubMed Web of Science ®Google Scholar
• Cramer, R., Patterson, D., & Bunce, J. (1988). Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. Journal of the American Chemical Society, 110, 5959–5967.10.1021/ja00226a005
   PubMed Web of Science ®Google Scholar
• Di Carlo, G., Mascolo, N., Izzo, A. A., & Capasso, F. (1999). Flavonoids: Old and new aspects of a class of natural therapeutic drugs. Life Sciences, 65, 337–353.10.1016/S0024-3205(99)00120-4
   PubMed Web of Science ®Google Scholar
• Elledge, R. M., & Osborne, C. K. (1997). Oestrogen receptors and breast cancer. BMJ, 314, 1843–1843.10.1136/bmj.314.7098.1843
   PubMed Web of Science ®Google Scholar
• Favia, A. D., Cavalli, A., Masetti, M., Carotti, A., & Recanatini, M. (2006). Three-dimensional model of the human aromatase enzyme and density functional parameterization of the iron containing protoporphyrin IX for a molecular dynamics study of heme-cysteinato cytochromes. Proteins: Structure, Function, and Bioinformatics, 62, 1074–1087.10.1002/prot.20829
   PubMed Web of Science ®Google Scholar
• Fink, B. N., Steck, S. E., Wolff, M. S., Britton, J. A., Kabat, G. C., Schroeder, J. C., … Gammon, M. D. (2006). Dietary flavonoid intake and breast cancer risk among women on Long Island. American Journal of Epidemiology, 165, 514–523.10.1093/aje/kwk033
   PubMed Web of Science ®Google Scholar
• Geladi, P., & Kowalski, B. R. (1986). Partial least-squares regression: A tutorial. Analytica Chimica Acta, 185, 1–17.10.1016/0003-2670(86)80028-9
   Web of Science ®Google Scholar
• Guallar, V., Baik, M. H., Lippard, S. J., & Friesner, R. A. (2003). Peripheral heme substituents control the hydrogen-atom abstraction chemistry in cytochromes P450. Proceedings of the National Academy of Sciences, 100, 6998–7002.10.1073/pnas.0732000100
   PubMed Web of Science ®Google Scholar
• Hulka, B. S., & Moorman, P. G. (2001). Breast cancer: Hormones and other risk factors. Maturitas, 38, 103–113, discussion 113–106.10.1016/S0378-5122(00)00196-1
   PubMed Web of Science ®Google Scholar
• Jeong, H. J., Shin, Y. G., Kim, I. H., & Pezzuto, J. M. (1999). Inhibition of aromatase activity by flavonoids. Archives of Pharmacal Research, 22, 309–312.10.1007/BF02976369
   PubMed Web of Science ®Google Scholar
• Jordan, V. C., Mittal, S., Gosden, B., Koch, R., & Lieberman, M. E. (1985). Structure-activity relationships of estrogens. Environmental Health Perspectives, 61, 97–110.10.1289/ehp.856197
   PubMed Web of Science ®Google Scholar
• Kao, Y. C., Zhou, C., Sherman, M., Laughton, C. A., & Chen, S. (1998). Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: A site-directed mutagenesis study. Environmental Health Perspectives, 106, 85–92.10.1289/ehp.9810685
   PubMed Web of Science ®Google Scholar
• Karkola, S., & Wähälä, K. (2009). The binding of lignans, flavonoids and coumestrol to CYP450 aromatase: A molecular modelling study. Molecular and Cellular Endocrinology, 301, 235–244.10.1016/j.mce.2008.10.003
   PubMed Web of Science ®Google Scholar
• Kellis, J. T., Jr., & Vickery, L. E. (1984). Inhibition of human estrogen synthetase (aromatase) by flavones. Science, 225, 1032–1034.10.1126/science.6474163
   PubMed Web of Science ®Google Scholar
• Kelsey, J. L., Gammon, M. D., & John, E. M. (1993). Reproductive factors and breast cancer. Epidemiologic Reviews, 15, 36–47.
   PubMed Web of Science ®Google Scholar
• Kim, K. H. (1995). Comparative molecular field analysis (CoMFA). In P. M. Dean (Ed.), Molecular similarity in drug design (pp. 291–331). Glasgow: Blackie Academic & Professional.10.1007/978-94-011-1350-2
   Google Scholar
• Klebe, G. (2006). Virtual ligand screening: Strategies, perspectives and limitations. Drug Discovery Today, 11, 580–594.10.1016/j.drudis.2006.05.012
   PubMed Web of Science ®Google Scholar
• Miller, W. R., Bartlett, J., Brodie, A. M. H., Brueggemeier, R. W., Di Salle, E., Lonning, P. E., … Goss, P. E. (2008). Aromatase inhibitors: Are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? The Oncologist, 13, 829–837.10.1634/theoncologist.2008-0055
   PubMed Web of Science ®Google Scholar
• Mirzaie, S., Chupani, L., Asadabadi, E. B., Shahverdi, A. R., & Jamalan, M. (2013). Novel inhibitor discovery against aromatase through virtual screening and molecular dynamic simulation: A computational approach in drug design. EXCLI Journal, 12, 168–183.
   PubMed Web of Science ®Google Scholar
• Murthy, J. N., Nagaraju, M., Sastry, G. M., Rao, A. R., & Sastry, G. N. (2006). Active site acidic residues and structural analysis of modelled human aromatase: A potential drug target for breast cancer. Journal of Computer-Aided Molecular Design, 19, 857–870.10.1007/s10822-005-9024-0
   Web of Science ®Google Scholar
• Neves, M. A., Dinis, T. C., Colombo, G., & Sá e Melo, M. L. (2009). Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. Journal of Medicinal Chemistry, 52, 143–150.10.1021/jm800945c
   PubMed Web of Science ®Google Scholar
• Pasqualini, J. R. (2004). The selective estrogen enzyme modulators in breast cancer: A review. Biochimica et Biophysica Acta, 1654, 123–143.
   PubMed Web of Science ®Google Scholar
• Peterson, J., Lagiou, P., Samoli, E., Lagiou, A., Katsouyanni, K., La Vecchia, C., … Trichopoulos, D. (2003). Flavonoid intake and breast cancer risk: A case-control study in Greece. British Journal of Cancer, 89, 1255–1259.10.1038/sj.bjc.6601271
   PubMed Web of Science ®Google Scholar
• Sakamoto, T., Horiguchi, H., Oguma, E., & Kayama, F. (2010). Effects of diverse dietary phytoestrogens on cell growth, cell cycle and apoptosis in estrogen-receptor-positive breast cancer cells. The Journal of Nutritional Biochemistry, 21, 856–864.10.1016/j.jnutbio.2009.06.010
   PubMed Web of Science ®Google Scholar
• Schuster, D., Laggner, C., Steindl, T. M., Palusczak, A., Hartmann, R. W., & Langer, T. (2006). Pharmacophore modeling and in silico screening for new P450 19 (aromatase) inhibitors. Journal of Chemical Information and Modeling, 46, 1301–1311.10.1021/ci050237k
   PubMed Web of Science ®Google Scholar
• Schüttelkopf, A. W., & van Aalten, D. M. (2004). PRODRG: A tool for high-throughput crystallography of protein–ligand complexes. Acta Crystallographica Section D Biological Crystallography, 60, 1355–1363.10.1107/S0907444904011679
   PubMed Web of Science ®Google Scholar
• Shoichet, B. K. (2004). Virtual screening of chemical libraries. Nature, 432, 862–865.10.1038/nature03197
   PubMed Web of Science ®Google Scholar
• Takahashi, M., Yamashita, K., & Numazawa, M. (2010). Probing the binding pocket of the active site of aromatase with 2-phenylaliphatic androsta-1,4-diene-3,17-dione steroids. Steroids, 75, 330–337.10.1016/j.steroids.2010.01.008
   PubMed Web of Science ®Google Scholar
• Vilar, S., & Costanzi, S. (2012). Predicting biological activities through QSAR analysis and docking-based scoring. Methods in Molecular Biology, 914, 271–284.
   PubMedGoogle Scholar
• Vilar, S., Cozza, G., & Moro, S. (2008). Medicinal chemistry and the molecular operating environment (MOE): Application of QSAR and molecular docking to drug discovery. Current Topics in Medicinal Chemistry, 8, 1555–1572.10.2174/156802608786786624
   PubMed Web of Science ®Google Scholar
• Wessjohann, L. A., Ruijter, E., Garcia-Rivera, D., & Brandt, W. (2005). What can a chemist learn from nature’s macrocycles-A brief, conceptual view. Molecular Diversity, 9, 171–186.10.1007/s11030-005-1314-x
   PubMed Web of Science ®Google Scholar
• Wold, S., Albano, C., Dunn, W. J., Esbensen, K., Hellberg, S., Johansson, E., … Sjostrom, M. (1984). Modelling data tables by principal components and PLS: Class patterns and quantitative predictive relations. Analusis, 12, 477–485.
   Google Scholar
• Yadav, M. R., Sabale, P. M., Giridhar, R., Zimmer, C., Haupenthal, J., & Hartmann, R. W. (2011). Synthesis of some novel androstanes as potential aromatase inhibitors. Steroids, 76, 464–470.10.1016/j.steroids.2010.12.013
   PubMed Web of Science ®Google Scholar